Pancreas Cancer, Predictive Cancer Model
Conditions
Brief summary
Importance: Lymphovascular invasion (LVI) is a poor prognosis pathologic feature in pancreatic ductal adenocarcinoma (PDAC) patients. Neoadjuvant therapy may bring survival benefits to these patients. Objective: To construct a preoperative model which could predict LVI in PDAC patients and further validate it in other cohorts. Design, Setting, and Participants: Patients from 3 three tertiary hospitals were included in this study. Univariate and multivariate Logistic regression analyses were conducted to define independent prediction factors of LVI. A nomogram was constructed based on the result of multivariate analysis.The predictive value of the model was assessed using receiver operating characteristic (ROC) curves and the maximum Youden index of the ROC curve was defined as the cut-off point. The calibration plot was utilized to assess the concordance of the model. The decision curve analyses (DCA) were applied to estimate the clinical benefit of using this model to predict LVI.
Interventions
None listed
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who were pathologically diagnosed as PDAC and received curative surgery.
Exclusion criteria
* Patients with distant metastasis; Patients who received neoadjuvant therapy; Patients with a survival time of less than 1 month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence-free survival | 10 years | Time from operation to the detection of recurrence or last follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 10 years | Time between surgical resection to death or the last follow-up. |
Countries
China
Contacts
Primary ContactJihui Hao, Dr
Backup ContactYiping Zou, Dr
Outcome results
None listed